Lantheus Grants Rights for the Use of its Microbubbles to SonoThera for its Ultrasound-Guided Nonviral Gene Therapy Platform
December 12, 2022 08:00 ET
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics,...
Lantheus Holdings, Inc. Announces Pricing of Offering of $500 Million Convertible Senior Notes due 2027
December 06, 2022 07:45 ET
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company” or “Lantheus”) (NASDAQ: LNTH), today announced the pricing of $500 million in aggregate principal...
Lantheus Holdings, Inc. Announces Proposed Offering of $500 Million Convertible Senior Notes due 2027
December 05, 2022 07:00 ET
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company” or “Lantheus”) (NASDAQ: LNTH), today announced that it intends to offer, subject to market conditions...
Lantheus Announces Appointment of Amanda Morgan as Senior Vice President, Commercial
November 29, 2022 08:00 ET
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics,...
Lantheus Announces the Approval of DEFINITY® (Perflutren Lipid Microsphere) by China’s NMPA
November 28, 2022 08:00 ET
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics,...
Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003
November 14, 2022 07:00 ET
|
Lantheus Holdings, Inc.
Collaboration pairs POINT’s expertise in next generation radioligand development and manufacturing with Lantheus’ commercial leadership in PSMA PET and radiopharmaceuticalsExpands Lantheus’ portfolio...
Lantheus to Present at the Jefferies London Healthcare Conference
November 09, 2022 08:30 ET
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics,...
Lantheus Reports Third Quarter 2022 Financial Results
November 03, 2022 07:00 ET
|
Lantheus Holdings, Inc.
Worldwide revenue of $239.3 million for the third quarter 2022, representing an increase of 134.4% from the prior year period GAAP net income of $61.2 million for the third quarter 2022, compared to...
Lantheus to Host Third Quarter 2022 Earnings Conference Call and Webcast on November 3, 2022, at 8:00 a.m. Eastern Time
October 20, 2022 08:30 ET
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on...
Lantheus Presentations at the European Association of Nuclear Medicine Annual Meeting Showcased Artificial Intelligence Data
October 17, 2022 09:14 ET
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics,...